CD19 and B-cell non-Hodgkin lymphoma: A side-by-side comparison study of 2G and 3G CARs was conducted to assess their in vivo behavior and therapeutic efficacy in patients with r/r B-cell non-Hodgkin’s lymphoma (NHL) using CD19-specific CAR-T cells.